Manfred Gessler

Prof. Manfred Gessler

orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Nature
Verified
Journal Article
Open access
PDF file
IPICGC PedBrain-Seq Project
ICGC PedBrain-Seq Project
SGSusanne N. Gröbner
Susanne N. Gröbner
IPIcgc Mmml-Seq Project
Icgc Mmml-Seq Project
BWBarbara C. Worst
Barbara C. Worst
JWJoachim Weischenfeldt
Joachim Weischenfeldt
Stefan PfisterStefan Pfister
Stefan Pfister
Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into cancer biology. Here we present a comprehensive analysis of genetic alterations in a pan-cancer cohort including 961 tumours from children, adolescents, and young adults, comprising 24 distinct molecular types of cancer. Using a standardized workflow, we identified marked differences in terms of mutation frequency and significantly mutated genes in comparison to previously analysed adult cancers. Genetic alterations in 149 putative cancer driver genes separate the tumours into two classes: small mutation and structural/copy-number variant (correlating with germline variants). Structural variants, hyperdiploidy, and chromothripsis are linked to TP53 mutation status and mutational signatures. Our data suggest that 7–8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.

1 February 1990 in Nature
Verified
Journal Article
Closed access
MGManfred Gessler
Manfred Gessler
APAnnemarie Poustka
Annemarie Poustka
WCWebster Cavenee
Webster Cavenee
RNRachael L. Neve
Rachael L. Neve
SOStuart H. Orkin
Stuart H. Orkin
GBGail A. P. Bruns
Gail A. P. Bruns

1 September 2001 in Cell
Verified
Journal Article
Closed access
BBBenoit G. Bruneau
Benoit G. Bruneau
Georges NemerGeorges Nemer
Georges Nemer
JSJoachim P. Schmitt
Joachim P. Schmitt
FCFrédéric Charron
Frédéric Charron
LRLynda Robitaille
Lynda Robitaille
JSJ.G. Seidman
J.G. Seidman

15 April 2004 in Genes & Development
Verified
Journal Article
Open access
PDF file
AFAndreas Fischer
Andreas Fischer
NSNina Schumacher
Nina Schumacher
MMManfred Maier
Manfred Maier
Michael SendtnerMichael Sendtner
Michael Sendtner
MGManfred Gessler
Manfred Gessler
The Delta–Notch signaling pathway plays a central role in the development of most vertebrate organs. The Hey family of bHLH transcription factors are direct targets of Notch signaling. Loss of Hey2 in the mouse leads to cardiac defects with high postnatal lethality. We have now generated a mouse Hey1 knockout that has no apparent phenotypic defect. The combined loss of Hey1 and Hey2, however, results in embryonic death after embryonic day 9.5 (E9.5) with a global lack of vascular remodeling and massive hemorrhage. Initial vasculogenesis appears unaffected, but all subsequently developing major vessels in the embryo and yolk sac are either small or absent. Furthermore, the placental labyrinth completely lacks embryonic blood vessels. Similar vascular defects are observed in Jagged1 and Notch1 knockout mice. In the latter we found Hey1 and Hey2 expression in yolk sacs to be strongly reduced. Remaining large arteries in both Notch1 and Hey1/Hey2 knockout mice fail to express the arterial endothelial markers CD44, neuropilin1, and ephrin-B2. This indicates that Hey1/Hey2 are essential transducers of Notch signals in cardiovascular development that may mediate arterial cell fate decision.

21 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKChristian Koelsche
Christian Koelsche
DSDaniel Schrimpf
Daniel Schrimpf
DSDamian Stichel
Damian Stichel
MSMartin Sill
Martin Sill
FSFelix Sahm
Felix Sahm
ADAndreas von Deimling
Andreas von Deimling
Sarcomas are malignant soft tissue and bone tumours affecting adults, adolescents and children. They represent a morphologically heterogeneous class of tumours and some entities lack defining histopathological features. Therefore, the diagnosis of sarcomas is burdened with a high inter-observer variability and misclassification rate. Here, we demonstrate classification of soft tissue and bone tumours using a machine learning classifier algorithm based on array-generated DNA methylation data. This sarcoma classifier is trained using a dataset of 1077 methylation profiles from comprehensively pre-characterized cases comprising 62 tumour methylation classes constituting a broad range of soft tissue and bone sarcoma subtypes across the entire age spectrum. The performance is validated in a cohort of 428 sarcomatous tumours, of which 322 cases were classified by the sarcoma classifier. Our results demonstrate the potential of the DNA methylation-based sarcoma classification for research and future diagnostic applications.

6 July 2008 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SSSakura Saburi
Sakura Saburi
IHIan Hester
Ian Hester
EFEvelyne Fischer
Evelyne Fischer
MPMarco Pontoglio
Marco Pontoglio
VEVera Eremina
Vera Eremina
HMHelen McNeill
Helen McNeill